SG11201702627UA - Enhanced loading of intact, bacterially derived vesicles with small molecule compounds - Google Patents
Enhanced loading of intact, bacterially derived vesicles with small molecule compoundsInfo
- Publication number
- SG11201702627UA SG11201702627UA SG11201702627UA SG11201702627UA SG11201702627UA SG 11201702627U A SG11201702627U A SG 11201702627UA SG 11201702627U A SG11201702627U A SG 11201702627UA SG 11201702627U A SG11201702627U A SG 11201702627UA SG 11201702627U A SG11201702627U A SG 11201702627UA
- Authority
- SG
- Singapore
- Prior art keywords
- intact
- small molecule
- molecule compounds
- derived vesicles
- bacterially derived
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
- A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Botany (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462059466P | 2014-10-03 | 2014-10-03 | |
| PCT/IB2015/057558 WO2016051389A1 (fr) | 2014-10-03 | 2015-10-02 | Charge améliorée de composés à petites molécules dans des vésicules d'origine bactérienne intactes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201702627UA true SG11201702627UA (en) | 2017-04-27 |
Family
ID=55629513
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201702627UA SG11201702627UA (en) | 2014-10-03 | 2015-10-02 | Enhanced loading of intact, bacterially derived vesicles with small molecule compounds |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US10328159B2 (fr) |
| EP (1) | EP3200765A4 (fr) |
| JP (1) | JP7029957B2 (fr) |
| CN (1) | CN106999444B (fr) |
| AU (1) | AU2015326407C1 (fr) |
| CA (2) | CA2963218C (fr) |
| SG (1) | SG11201702627UA (fr) |
| TW (1) | TWI781904B (fr) |
| WO (1) | WO2016051389A1 (fr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2015326407C1 (en) * | 2014-10-03 | 2021-06-24 | Engeneic Molecular Delivery Pty Ltd | Enhanced loading of intact, bacterially derived vesicles with small molecule compounds |
| KR101708424B1 (ko) * | 2015-03-04 | 2017-02-20 | 전남대학교산학협력단 | 코리네박테리움 속 박테리아 및 이로부터 유래된 미니셀 그리고 이의 용도 |
| US10399964B2 (en) | 2017-03-30 | 2019-09-03 | The University Of Kansas | Coumarin-linked taxanes for detection and circumvention of cellular efflux |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH04334377A (ja) | 1990-12-31 | 1992-11-20 | Akzo Nv | 酸−不安定性リンカー分子 |
| GB2315067B (en) | 1996-07-11 | 2000-02-16 | Pharmacia Spa | Morpholinyl anthracycline derivatives |
| US9107949B2 (en) * | 1996-11-12 | 2015-08-18 | The University Of Akron | Method for using naturally occurring gas vesicles as ultrasound contrast agent |
| US20040138168A1 (en) * | 1999-04-21 | 2004-07-15 | Wyeth | Methods and compositions for inhibiting the function of polynucleotide sequences |
| BR0010316A (pt) | 1999-05-11 | 2004-04-27 | Ortho Mcnell Pharmaceutical In | Método e sistema para obtenção de regimes de dosagem otimizados de epo para uma resposta farmacodinâmica/farmacocinética desejada em um paciente |
| US6521431B1 (en) | 1999-06-22 | 2003-02-18 | Access Pharmaceuticals, Inc. | Biodegradable cross-linkers having a polyacid connected to reactive groups for cross-linking polymer filaments |
| AU2005203401A1 (en) * | 2000-03-08 | 2006-02-16 | Gerhart Graupner | Targeting bioactive materials via somatostatin receptors |
| US20030194798A1 (en) | 2001-05-24 | 2003-10-16 | Surber Mark W. | Minicell compositions and methods |
| US20050222057A1 (en) | 2001-10-15 | 2005-10-06 | Himanshu Brahmbhatt | Intact minicells as vectors for dna transfer and gene therapy in vitro and in vivo |
| CN1313622C (zh) * | 2002-08-02 | 2007-05-02 | 赵翀 | 高通量细胞生物芯片检测技术及试剂盒 |
| WO2004082689A1 (fr) * | 2003-03-18 | 2004-09-30 | Pharmacia Italia Spa | Polytherapie comprenant l'administration combinee de nemorubicine et d'un inhibiteur de la cyclo-oxygenase-2 |
| US7611885B2 (en) | 2003-06-24 | 2009-11-03 | Engeneic Molecular Delivery Pty, Ltd. | Pharmaceutically compatible method for purifying intact bacterial minicells |
| CA2530224A1 (fr) | 2003-07-09 | 2005-02-24 | California Pacific Medical Center | Detection a distance de la diffusion de substances aux cellules |
| EP1690089A1 (fr) * | 2003-11-26 | 2006-08-16 | Applera Corporation | Procedes et compositions d'essai de liaison homogene fluorogene |
| CA2549840C (fr) | 2003-12-09 | 2012-03-20 | Engeneic Molecular Delivery Pty Ltd. | Administration ciblee de genes a des cellules mammiferes non phagocytaires par l'intermediaire de minicellules intactes derivees de bacteries |
| CN1925873B (zh) | 2004-02-02 | 2011-02-09 | 恩杰内克分子递送有限公司 | 经细菌来源的完整微细胞在体外将药物靶向递送至哺乳动物细胞的组合物和方法 |
| MXPA06014691A (es) * | 2004-06-30 | 2008-03-11 | Novartis Ag | Conjugados de anticuerpo y derivados de duocarmicina como agentes anti-tumorales. |
| AU2005276145C1 (en) | 2004-08-26 | 2011-01-06 | Engeneic Molecular Delivery Pty Ltd | Delivering functional nucleic acids to mammalian cells via bacterially derived, intact minicells |
| US7341720B2 (en) | 2005-04-06 | 2008-03-11 | Genzyme Corporation | Targeting of glycoprotein therapeutics |
| PT2712618T (pt) * | 2006-06-23 | 2017-01-26 | Engeneic Molecular Delivery Pty Ltd | Entrega localizada de fármacos, ácidos nucleicos terapêuticos e ácidos nucleicos funcionais a células de mamíferos por meio de células bacterianas exterminadas intactas |
| IE20060565A1 (en) * | 2006-07-28 | 2008-02-06 | Eurand Pharmaceuticals Ltd | Drug delivery system based on regioselectively amidated hyaluronic acid |
| CA2666697C (fr) * | 2006-10-19 | 2015-03-31 | Nanocarrier Co., Ltd. | Copolymere bloc pour complexe medicamenteux et composition pharmaceutique |
| PL2865755T3 (pl) | 2007-03-30 | 2017-08-31 | Engeneic Molecular Delivery Pty Ltd | Nienaruszone komórki pochodzenia bakteryjnego, obejmujące regulatorowy RNA |
| JP5781929B2 (ja) * | 2008-07-15 | 2015-09-24 | ノバルティス アーゲー | 免疫原性の両親媒性ペプチド組成物 |
| MX2012002723A (es) | 2009-09-02 | 2012-04-11 | Novartis Ag | Composiciones inmunogenicas que incluyen moduladores de la actividad de receptores tipo toll. |
| ES2776983T3 (es) | 2010-09-21 | 2020-08-03 | Cristal Delivery B V | Moléculas enlazadoras biodegradables ajustables para la conjugación transitoria de componentes en sistemas de administración de fármacos, y sistemas de administración de fármacos preparados con ellas |
| US20120121615A1 (en) | 2010-11-17 | 2012-05-17 | Flygare John A | Alaninyl maytansinol antibody conjugates |
| EP2646456B1 (fr) | 2010-12-02 | 2015-01-21 | Nerviano Medical Sciences S.r.l. | Procédé pour la préparation de dérivés de la morpholinyle anthracycline |
| US20130071482A1 (en) | 2011-09-20 | 2013-03-21 | The University Of Kentucky Research Foundation | Block copolymer cross-linked nanoassemblies as modular delivery vehicles |
| WO2013048734A1 (fr) * | 2011-09-28 | 2013-04-04 | Tufts Medical Center, Inc. | Traitement et prévention des maladies cardiovasculaires à l'aide de vésicules, microvésicules et exosomes lipidiques d'origine cellulaire |
| MX359410B (es) * | 2011-12-13 | 2018-09-27 | Engeneic Molecular Delivery Pty Ltd | Minicélulas intactas derivadas bacterialmente para suministro de agentes terapéuticos a tumores cerebrales. |
| EP2708243A1 (fr) * | 2012-09-17 | 2014-03-19 | OntoChem GmbH | Molécules cytotoxiques liés à un ligand de récepteur |
| CA2900454A1 (fr) | 2013-02-07 | 2014-08-14 | Glaxosmithkline Biologicals Sa | Compositions pharmaceutiques contenant des vesicules |
| JP6538031B2 (ja) | 2013-10-04 | 2019-07-03 | エンジーンアイシー モレキュラー デリバリー ピーティーワイ リミテッド | 薬物を負荷した二重特異性リガンド標的化ミニ細胞およびインターフェロン−γを用いた併用腫瘍治療 |
| JP5704222B1 (ja) | 2013-11-27 | 2015-04-22 | 株式会社豊田自動織機 | 繊維強化複合材料 |
| AU2015326407C1 (en) | 2014-10-03 | 2021-06-24 | Engeneic Molecular Delivery Pty Ltd | Enhanced loading of intact, bacterially derived vesicles with small molecule compounds |
| AU2017339841A1 (en) | 2016-10-06 | 2019-05-02 | Engeneic Molecular Delivery Pty Ltd | Bacterial minicells for delivering nucleic acid adjuvants and methods of using the same |
| US11504402B2 (en) | 2018-07-23 | 2022-11-22 | Engenelc Molecular Delivery Pty Ltd | Compositions comprising bacterially derived minicells and methods of using the same |
| JP2022516347A (ja) | 2019-01-04 | 2022-02-25 | エンジーンアイシー モレキュラー デリバリー ピーティーワイ リミテッド | 腫瘍性疾患の治療のためのカプセル化グリコリピド抗原 |
-
2015
- 2015-10-02 AU AU2015326407A patent/AU2015326407C1/en active Active
- 2015-10-02 CN CN201580065821.6A patent/CN106999444B/zh active Active
- 2015-10-02 JP JP2017517692A patent/JP7029957B2/ja active Active
- 2015-10-02 TW TW104132594A patent/TWI781904B/zh active
- 2015-10-02 EP EP15846818.1A patent/EP3200765A4/fr active Pending
- 2015-10-02 WO PCT/IB2015/057558 patent/WO2016051389A1/fr active Application Filing
- 2015-10-02 SG SG11201702627UA patent/SG11201702627UA/en unknown
- 2015-10-02 CA CA2963218A patent/CA2963218C/fr active Active
- 2015-10-02 US US14/873,776 patent/US10328159B2/en active Active
- 2015-10-02 CA CA3211718A patent/CA3211718A1/fr active Pending
-
2019
- 2019-03-22 US US16/362,562 patent/US11052157B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA3211718A1 (fr) | 2016-04-07 |
| AU2015326407C1 (en) | 2021-06-24 |
| WO2016051389A1 (fr) | 2016-04-07 |
| JP7029957B2 (ja) | 2022-03-04 |
| US20190216946A1 (en) | 2019-07-18 |
| CN106999444B (zh) | 2023-12-12 |
| TWI781904B (zh) | 2022-11-01 |
| EP3200765A4 (fr) | 2018-05-30 |
| CA2963218C (fr) | 2023-10-24 |
| US11052157B2 (en) | 2021-07-06 |
| US20160095941A1 (en) | 2016-04-07 |
| US10328159B2 (en) | 2019-06-25 |
| EP3200765A1 (fr) | 2017-08-09 |
| JP2017530152A (ja) | 2017-10-12 |
| AU2015326407B2 (en) | 2021-03-18 |
| AU2015326407A1 (en) | 2017-04-20 |
| TW201628606A (zh) | 2016-08-16 |
| CA2963218A1 (fr) | 2016-04-07 |
| CN106999444A (zh) | 2017-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1257760A1 (zh) | 多特異性抗體 | |
| ZA201605660B (en) | Multispecific antibodies | |
| IL249003A0 (en) | Multispecific antibody structures | |
| PL3227332T3 (pl) | Wielospecyficzne przeciwciała | |
| PL3149241T3 (pl) | Celuloza mikrofibrylowana | |
| GB2539344B (en) | Partition mobility for partitions with extended code | |
| GB201414823D0 (en) | Multispecific antibodies | |
| GB201421379D0 (en) | Molecule | |
| EP3119755A4 (fr) | Procédé de préparation d'un composé antifongique | |
| EP3119754A4 (fr) | Préparation d'un composé antifongique | |
| EP3178285A4 (fr) | Réseau d'auto-optimisation (son) pour double connectivité | |
| EP3119748A4 (fr) | Procédé de préparation d'un composé antifongique | |
| EP3119746A4 (fr) | Procédé de préparation d'un composé antifongique | |
| EP3119745A4 (fr) | Procédé de préparation d'un composé antifongique | |
| EP3119771A4 (fr) | Procédé associé à un composé antifongique | |
| EP3119764A4 (fr) | Procédé de préparation d'un composé antifongique | |
| EP3119749A4 (fr) | Procédé de préparation de composé antifongique | |
| GB201409047D0 (en) | Cellulose microfibrils | |
| EP3256856A4 (fr) | Analyseur multiplexé de molécule unique | |
| EP3207036A4 (fr) | Nouveaux agents anticancéreux à petites molécules | |
| EP3170932A4 (fr) | Structure de maille | |
| SG11201702627UA (en) | Enhanced loading of intact, bacterially derived vesicles with small molecule compounds | |
| GB201520883D0 (en) | Single molecule controls | |
| GB201409759D0 (en) | Molecule | |
| GB201403479D0 (en) | Molecule |